NCT07558382 Global Initiative on Takayasu Arteritis (GITA)
| NCT ID | NCT07558382 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marmara University |
| Condition | Takayasu Arteritis (TAK) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-08-05 |
| Primary Completion | 2035-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-08-05 with a primary completion date of 2035-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Takayasu's Arteritis Global Registry aims to bring a large group of patients from different parts of the world to analyse and compare the patients' demographic, clinical, laboratory, radiological and prognostic features with outcomes, approaches to diagnosis, assessment, management and therapeutic interventions in different centers. The present project provides for both a retrospective and a prospective longitudinal study. The study is designed as retrospective for patients already diagnosed with TAK and treated with available treatments. Also, the study is designed as prospective for patients diagnosed with TAK after the initiation of the Registry or the adhesion to the project. This is thought as a multicentre, international study addressed to all Centers that will want to contribute to the present project. The study is non-interventional: demographic, clinical and therapeutic data required over time are collected with the routine diagnostic, clinical and therapeutic procedures usually carried out for the optimal management of patients and according with good clinical practice.
Eligibility Criteria
Inclusion Criteria: * Each patient must fullfill the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis. * Patients (or legally acceptable representatives of subjects enrolled) have to * provide informed and free agreement to participate in the study and to disclose any medical event to the investigator. The parents or legally acceptable representative and the adolescent subject must be willing and able to comply with the study protocol requirements for the duration of the study * freely sign written and dated informed consent after being duly informed of the nature, significance, and implications of the study; * be informed that the patient enrolled may withdraw consent at any time without prejudice to future medical care. Exclusion Criteria: Patients must be excluded from the study when the following criteria are observed: * The patient does not full-fill the ACR 1990 or ACR/EULAR 2021 criteria for Takayasu arteritis * informed consent/assent is not provided and signed
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07558382 clinical trial?
This trial is open to participants of all sexes, studying Takayasu Arteritis (TAK). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07558382 currently recruiting?
Yes, NCT07558382 is actively recruiting participants. Contact the research team at falibaz@gmail.com for enrollment information.
Where is the NCT07558382 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07558382 clinical trial?
NCT07558382 is sponsored by Marmara University. The trial plans to enroll 1,000 participants.